Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 4.5% – Should You Sell?

by · The Cerbat Gem

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Get Free Report) was down 4.5% during trading on Thursday . The company traded as low as $0.31 and last traded at $0.32. Approximately 28,860,322 shares changed hands during mid-day trading, a decline of 7% from the average daily volume of 31,034,150 shares. The stock had previously closed at $0.33.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Tonix Pharmaceuticals in a research note on Wednesday. They set a “hold” rating on the stock.

View Our Latest Report on Tonix Pharmaceuticals

Tonix Pharmaceuticals Stock Performance

The company’s 50 day simple moving average is $0.23 and its 200 day simple moving average is $0.37. The stock has a market cap of $59.73 million, a PE ratio of -0.01 and a beta of 2.23. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $1.80. The business had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. Analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.

Tonix Pharmaceuticals Company Profile

(Get Free Report)

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

Recommended Stories